Metabolic Effects of Androgenicity in Aging Men and Women
NCT ID: NCT00680797
Last Updated: 2017-06-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
33 participants
INTERVENTIONAL
2005-01-01
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators plan to study 60 subjects. All of these subjects will be healthy older men between the ages of 60-85 years old who are not on testosterone therapy. Subjects that are screened who have any clinically significant abnormalities detected on their screening physical exam or laboratory testing (e.g. Prostate Specific Antigen \> 4), who have a history of prostate cancer, polycythemia, or who cannot take testosterone will not be included.
If a subject is eligible to participate after initial screening, that subject will take medications to adjust their hormone levels and have tests performed that measure insulin sensitivity and adiposity before and after these hormone medications. The outcomes that will be measured are: 1) insulin sensitivity, 2) hormone levels (total and free testosterone levels, sex hormone-binding globulin levels) and 3) body composition and abdominal adiposity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
NCT01686828
Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men
NCT00365794
Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version
NCT07092527
Insulin Sensitivity in Men With the Metabolic Syndrome
NCT00433173
Effects of Replacement Therapy With Sexual Steroid Hormones on the Insulin Sensitivity of Hypogonadal Man
NCT02847806
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
+T +E
+Testosterone, +Estrogen
Testosterone
Testosterone gel
Estrogen
Estrogen patch
+T -E
+Testosterone, -Estrogen
Testosterone
Testosterone gel
-T +E
-Testosterone, +Estrogen
Estrogen
Estrogen patch
-T -E
-Testosterone, -Estrogen
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Testosterone
Testosterone gel
Estrogen
Estrogen patch
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* non-diabetic fasting glucose and 2-hour oral glucose tolerance test (OGTT)
* overall good general medical health and signed informed consent
* willing to travel to West Los Angeles VA and University of California, Los Angeles in Los Angeles, California
Exclusion Criteria
* or other symptom or history of a significant underlying medical or psychiatric illness
* BMI \< 20 or \> 40
* subjects already on testosterone therapy or medications that might influence glucose regulation or hormone levels
* subjects with a history of deep venous thromboses, pulmonary embolism, breast cancer, prostate cancer, polycythemia or other contraindications to estrogen or testosterone
60 Years
85 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cathy C Lee, PhD
Role: PRINCIPAL_INVESTIGATOR
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
West Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ARCD-034-04F
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.